GDGabriella Grossi de Lima Dias

Gabriella Grossi de Lima Dias

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Gabriella Grossi de Lima Dias has a total of 6 co-authors. Here are the top co-authors by number of shared publications:

  • Amanda Alves Nascimento

    Laboratory Neurobiology of the retina, Biology Institute, Department of Neurobiology and Program of Neurosciences Fluminense Federal University Rio de Janeiro Brazil

    1 shared publication
  • Danniel Pereira‐Figueiredo

    Laboratory Neurobiology of the retina, Biology Institute, Department of Neurobiology and Program of Biomedical Sciences Fluminense Federal University Rio de Janeiro Brazil

    1 shared publication
  • Gabriel Ferreira dos Santos

    Laboratory Neurobiology of the retina, Biology Institute, Department of Neurobiology and Program of Biomedical Sciences Fluminense Federal University Rio de Janeiro Brazil

    1 shared publication
  • Karin da Costa Calaza

    Laboratory of Retinal Neurobiology, Department of Neurobiology, Institute of Biology, Fluminense Federal University, Niterói 242102401, RJ, Brazil

    1 shared publication
  • Mariana Rodrigues Pereira

    Chemical Signaling Laboratory, Biology Institute, Department of Neurobiology, Program of Neurosciences and Program in Science and Biotechnology Fluminense Federal University Rio de Janeiro Brazil

    1 shared publication
  • Rafael Brito

    Graduate Program of Neurosciences, Institute of Biology, Fluminense Federal University, Niterói 242102401, RJ, Brazil

    1 shared publication

Latest Publications

  • Open Access

    Acute caffeine treatment protects the developing retina from ischemia‐induced cell death

    by Amanda Alves Nascimento, Danniel Pereira‐Figueiredo, Gabriella Grossi de Lima Dias, Gabriel Ferreira dos Santos, Mariana Rodrigues Pereira, Rafael Brito, Karin C Calaza

    Ischemic damage to the retina during development can lead to irreversible neuronal loss, driven in part by excitotoxic mechanisms and energy deprivation. While two‐day caffeine exposure has previously been shown to confer neuroprotection in this context, it remained unclear whether acute administration during an ischemic event could yield similar benefits. In this study, we used an ex vivo model of oxygen and glucose deprivation (OGD) in chick embryo retinas to investigate whether a single, acute dose of caffeine applied during the insult reduces cell death and engages intracellular survival pathways. Results showed a significant reduction in OGD‐induced cytotoxicity by caffeine exposure. However, unlike in the context of chronic exposure, acute caffeine exposure did not increase BDNF expression. Furthermore, antioxidant agents failed to mimic caffeine's protective effects, and acute caffeine exposure did not induce the expression of antioxidant response genes, nor oxidative stress or VEGF expression, suggesting that oxidative stress mitigation is not the primary mechanism for this effect. However, pharmacological antagonism of adenosine A 2A receptors with ZM241385 reproduced the neuroprotective effects of caffeine and reduced extracellular glutamate levels during OGD. These findings indicate that acute caffeine administration protects the developing retina primarily through A 2A receptor antagonism and inhibition of glutamate excitotoxicity, rather than by activating canonical survival signaling pathways. This supports the potential use of caffeine as a rapid neuroprotective agent during acute ischemic events in the immature central nervous system.